Disclaimer: The medications discussed in this article may include compounded preparations from a licensed 503A compounding pharmacy. Compounded medications have not been reviewed or approved by the FDA and are not the same as commercially available FDA-approved products. This content is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Please consult a licensed healthcare provider for personalized clinical guidance.
A patient came in last year who had spent over $3,000 in a single quarter at an IV therapy clinic. The sessions were helping, she said. She felt sharper after each infusion, her energy held better for a week or so. Then her schedule changed and the costs caught up with her, and she stopped entirely. Six weeks later she felt exactly the way she had before she started.
That story reveals something important about NAD IV therapy and the biology of NAD+ restoration: the benefit tracks the consistency of replenishment, not the magnitude of any single dose. Understanding why requires a look at what NAD+ actually does at the cellular level and how its decline with age is driven by mechanisms that do not stop between infusion appointments.
What NAD+ Does and Why Restoration Matters
Nicotinamide adenine dinucleotide is a coenzyme found in every cell of the body. Its most fundamental role is as an electron carrier in metabolic redox reactions, shuttling reducing equivalents into the mitochondrial electron transport chain to drive ATP production. Without sufficient NAD+ to complete this cycling, mitochondrial energy output falls and cells become metabolically constrained.
But NAD+ is also a consumed substrate, not just a cycling carrier, in three critical regulatory pathways. Sirtuins, a family of seven deacetylase enzymes designated SIRT1 through SIRT7, require NAD+ for every catalytic cycle. SIRT1 deacetylates histones and transcription factors to regulate gene expression for inflammation, metabolic adaptation, and stress resistance. SIRT3 governs mitochondrial protein acetylation and protects against oxidative damage. PARPs, or poly-ADP-ribose polymerases, also consume NAD+ as a substrate for DNA repair. CD38, an enzyme with NAD+ glycohydrolase activity involved in immune signaling and calcium mobilization, is another major consumer. These are not minor diversions. They compete for the same NAD+ pool that the mitochondria need to sustain energy output.
The research supporting NAD+ restoration is mechanistically well understood. A landmark 2016 clinical trial led by Charles Brenner and Samuel Trammell, published in Nature Communications, was the first controlled human trial of nicotinamide riboside, an NAD+ precursor. The trial showed dose-dependent increases in blood NAD+ metabolites in healthy human subjects, with blood NAD+ rising as much as 2.7-fold after a single dose. No serious adverse events were observed across 36 days of observation. (PubMed)
Why NAD+ Declines With Age
NAD+ decline is driven by specific, identifiable mechanisms that accelerate over time. CD38 expression increases substantially with age and with chronic low-grade inflammation. As CD38 upregulates, it hydrolyzes NAD+ at an increasing rate, outpacing the body’s capacity to resynthesize it. This is compounded by PARP hyperactivation: decades of accumulated DNA damage mean more strand breaks and more PARP recruitment, each episode drawing down the NAD+ pool. At the same time, NAMPT, the rate-limiting enzyme in the NAD+ salvage pathway that recycles nicotinamide back into NAD+, declines in activity with age. The synthesis side weakens while the consumption side accelerates.
This mechanism matters for treatment decisions. If the problem were simply inadequate dietary intake, a single large dose once a month might suffice. But the problem is continuous enzymatic consumption that does not pause between appointments. The replenishment strategy needs to match the consumption pattern.
NAD IV Therapy: The Clinical Case and the Real Limitations
Intravenous NAD+ infusion delivers the coenzyme directly into circulation, achieving 100 percent bioavailability. A standard IV session uses 250 to 1,000 mg of NAD+ dissolved in saline, infused over two to four hours. The acute elevation in plasma NAD+ is rapid and substantial. For patients with severe depletion or who are going through addiction recovery protocols, that acute loading can be clinically appropriate and the high peak concentration may have specific therapeutic value.
But for the large majority of patients pursuing longevity, cognitive performance, metabolic health, and energy, the IV model creates practical barriers that undermine the very consistency the biology requires. Sessions cost $400 to $600 each. They require patients to take two to four hours out of their day, travel to a clinic, and sit attached to an IV line. Loading protocols often call for four to ten sessions over two to four weeks, a financial and logistical burden most patients cannot sustain. When patients stop, the benefit stops. NAD+ does not accumulate indefinitely. The CD38 enzymes keep working. The PARPs keep responding to DNA damage. The NAD+ that was transiently elevated is metabolized and cleared within hours to days, and the problem reasserts itself.
Why Subcutaneous Injection Achieves Comparable Systemic Results
Subcutaneous NAD+ injection delivers the compound into the tissue just below the skin, where it is absorbed steadily into systemic circulation. The bioavailability is lower than IV, approximately 70 to 80 percent, but the pharmacokinetics are actually favorable for the sustained cellular replenishment that sirtuin activation requires. Rather than a single large spike that peaks and then clears, subcutaneous injection delivers a more gradual, sustained elevation of plasma NAD+.
What the research supports is that for long-term outcomes, frequency of replenishment matters more than the route of a single large dose. Consistent, repeated elevation of NAD+ supports ongoing sirtuin activity, sustained mitochondrial function, and continuous DNA repair processes. The sirtuin enzymes require NAD+ as a stoichiometric substrate: every deacetylation reaction consumes one molecule of NAD+. Maintaining the baseline concentration that keeps SIRT1 and SIRT3 active requires steady replenishment, not periodic flooding.
Yoshino and colleagues, writing in Science in 2021, conducted a randomized, double-blind, placebo-controlled trial showing that NAD+ precursor supplementation increased intramuscular NAD+ levels by 38 percent and improved insulin sensitivity in skeletal muscle by 25 percent in prediabetic women, with SIRT1 activation confirmed by RNA sequencing. (PubMed) The delivery route in that trial was oral, not IV — reinforcing that tissue-level NAD+ elevation sufficient to activate sirtuins and improve metabolic function does not require intravenous delivery.
The Cost Reality and What Sustainability Actually Means
At Precision Telemed, the NAD+ program is $149.99 per month. A single IV session at a typical IV therapy clinic costs more than that. Two IV sessions per month, a conservative maintenance schedule by those clinics’ own protocols, costs $800 to $1,200 monthly.
Sustainable, in this context, is not a marketing word. It is a biological requirement. A therapy that raises NAD+ for three weeks and then disappears for a month does not confer lasting sirtuin activation. It does not produce durable mitochondrial improvement. The subcutaneous model at home, administered twice weekly during loading and then weekly for maintenance, is designed to match the biology. It keeps the NAD+ pool elevated continuously rather than cycling it sharply up and down.
Patients self-inject using a small insulin-gauge needle into the abdomen or outer thigh. The process takes under two minutes. There is no clinic visit, no IV line, and no $500 session fee.
How I Structure NAD+ Protocols at Precision Telemed
For most patients, I start with twice-weekly subcutaneous injections for the first four to six weeks as a loading phase, then taper to once weekly for maintenance. Patients report improvements in mental clarity, energy stability, sleep quality, and exercise recovery within the first two to four weeks of consistent use. The cognitive improvements, which are often what patients notice first — are consistent with SIRT1-mediated neurological effects and the mitochondrial energy requirements of neural tissue.
For patients managing metabolic conditions, age-related fatigue, or neurological symptoms, I may maintain the twice-weekly schedule longer before stepping down. The async model at Precision Telemed allows follow-up on lab values and symptom tracking without requiring in-person visits.
FAQ
Q: Is subcutaneous NAD+ as effective as IV therapy? For most patients pursuing sustained longevity and metabolic benefits, yes. IV therapy achieves a higher acute plasma NAD+ peak, but subcutaneous injection at regular intervals maintains the consistent baseline elevation that drives ongoing sirtuin activation and mitochondrial support. For sirtuin enzymes that require NAD+ as a stoichiometric substrate in every catalytic cycle, frequency of replenishment matters more than the magnitude of any single dose.
Q: How often should subcutaneous NAD+ be administered? Most protocols use twice weekly for the first four to six weeks as a loading phase, then once weekly for ongoing maintenance. The treating provider adjusts this based on symptoms and treatment goals.
Q: What does NAD+ actually do in the body? NAD+ functions as an electron carrier in mitochondrial redox reactions that produce ATP, and as a consumed substrate for sirtuin enzymes (SIRT1-7), PARP DNA repair enzymes, and CD38. Its decline with age reduces cellular energy output, impairs DNA repair, and suppresses sirtuin-mediated gene regulation.
Q: Why does NAD+ decline with age? CD38 expression increases with age and chronic inflammation, hydrolyzing NAD+ at an accelerating rate. PARP hyperactivation from accumulated DNA damage adds to consumption. Meanwhile, NAMPT, the rate-limiting enzyme in the NAD+ salvage pathway, declines in activity. The result is a progressive imbalance between consumption and synthesis.
Q: Is self-injection at home safe? Yes, with proper instruction. Subcutaneous injection with an insulin-gauge needle into the abdomen or outer thigh is a well-established and low-risk technique. Precision Telemed patients receive complete injection education as part of their onboarding.
Q: How is Precision Telemed’s NAD+ program different from an IV clinic? Cost and consistency are the primary differences. At $149.99 per month, the program costs a fraction of a single IV session at most clinics. It is delivered to the patient’s door, administered at home in under two minutes, and managed asynchronously by a licensed provider. The weekly or twice-weekly schedule is designed to maintain NAD+ at biologically active levels continuously rather than episodically.
Q: Can NAD+ help with brain fog and cognitive performance? The research on SIRT1-mediated neurological regulation and the mitochondrial energy requirements of neural tissue is compelling, and many patients in our practice report meaningful improvements in clarity and sustained mental energy within the first few weeks of consistent use. This is positioned as a supportive intervention that addresses a documented biological mechanism — not a treatment for any diagnosed neurological condition.
References
- Trammell SA et al. Nicotinamide riboside is uniquely and orally bioavailable in healthy humans. Nat Commun. 2016;7:12948. PubMed
- Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PubMed
To speak with one of our licensed providers about whether this is right for you, visit precisiontelemed.com.
This article is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult your healthcare provider.